Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

Pediatric Nephrology

Volumn 26, Issue 10, 2011, Pages 1919-1920

  Bouts, Antonia ^a   Monnens, Leo ^b   Davin, Jean Claude ^a   Struijk, Geertrude ^c   Spanjaard, Lodewijk ^c  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MENINGOCOCCUS VACCINE; PENICILLIN G;

AGE DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; BACTERIUM ISOLATE; HUMAN; INCIDENCE; INFECTION PREVENTION; LETTER; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; SEROPREVALENCE; VACCINATION;

ADOLESCENT; ADULT; AGING; ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; YOUNG ADULT;

EID: 80052290190     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1929-3     Document Type: Letter

References (9)

1. RA Brodsky NS Young E Antonioli AM Risitano H Schrezenmeier J Schubert A Gaya L Coyle C de Castro JP Maciejewski M Bessler HA Kroon RP Rother P Hillmen 2008 Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Blood 111 1840 1847 18055865 1:CAS:528:DC%2BD1cXisVeisrs%3D 10.1182/blood-2007-06-094136 (Pubitemid 351451491)
2. P Hillmen M Elebute R Kelly A Urbano-Ispizua A Hill RP Rother G Khursigara CL Fu M Omine P Browne W Rosse 2010 Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria Am J Hematol 85 553 559 20658586 1:CAS:528: DC%2BC3cXhtV2ntrnI 10.1002/ajh.21757
3. A Dmytrijuk K Robie-Suh MH Cohen D Rieves K Weiss R Pazdur 2008 FDA report: eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal hemoglobinuria Oncologist 13 993 1000 18784156 1:CAS:528: DC%2BD1cXhtlaksrrO 10.1634/theoncologist.2008-0086
4. P Gardner 2006 Prevention of meningococcal disease N Engl J Med 355 1466 1473 17021322 1:CAS:528:DC%2BD28XhtVGgtrvK 10.1056/NEJMcp063561 (Pubitemid 44511561)
5. Netherlands Reference laboratory for bacterial meningitis (AMC/RIVM). Bacterial Meningitis in the Netherlands; annual report 2009. Amsterdam: University of Amsterdam, 2010
6. AM Waters C Licht 2011 aHUS caused by complement dysregulation: new therapies on the horizon Pediatr Nephrol 26 1 41 57 20556434 10.1007/s00467-010-1556-4
7. ZA Memish G Dbaibo M Montellano VP Verghese H Jain AP Dubey V Bianco M Van der Wielen S Gatchalian JM Miller 2011 Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licenced-ACWY polysaccharide vaccine with an acceptable safety profile Ped Infect Dis J 30 4 e56 e62 10.1097/INF.0b013e31820e6e02
8. LH Harrison CL Trotter ME Ramsay 2009 Global epidemiology of meningococcal disease Vaccine 27S B51 B63 10.1016/j.vaccine.2009.04.063
9. CA Hart APJ Thomson 2006 Meningococcal disease and its management in children BMJ 333 685 6090 17008668 10.1136/bmj.38968.683958.AE (Pubitemid 44521011)